Skip to main content
PsiQuantumPartnership

PsiQuantum and National Cancer Center Japan Partner to Accelerate Drug Discovery for Healthcare

What happened

PsiQuantum partners with National Cancer Center.

Source

Article excerpt

Highlighted: the sentence this signal was extracted from

PsiQuantum and National Cancer Center Japan partner to accelerate drug discovery for healthcare. March 12, 2026 Press play to listen to this content PALO ALTO, Calif., March 12, 2026 - PsiQuantum announced today that the company has signed a collaborative research agreement with the National Cancer Center Japan, a leading cancer treatment and research facility, to advance applications in oncology and healthcare for utility-scale quantum computers. This new agreement underscores the enormous potential for utility-scale quantum computing across the healthcare value chain, specifically in research and development, resource allocation, and patient outcomes in cancer treatment. Under the newly formed collaboration, PsiQuantum will work alongside the National Cancer Center Japan to advance fault-tolerant quantum algorithm development and collaborate with the National Cancer Center Japan and other leading pharmaceutical companies in Japan in the development of clinically relevant quantum applications. The partnership will also utilize PsiQuantum's software suite, Construct - a secure, end-to-end platform for designing, analyzing, and optimizing algorithms for fault-tolerant quantum computing. "PsiQuantum is proud to work alongside the National Cancer Center Japan as we explore what utility-scale quantum computing will be able to deliver in designing new treatments for the...

Keep reading with a free account

The rest of this article, and every signal for PsiQuantum, is in your free account.

Extracted by Autobound

From the Signal API record
Event
Partnership

What this signalsA new partnership often opens integration and co-selling work.

More partnership signals at other companies

The full record

From the Signal API record

Details

Category
Partners with

Extraction

Confidence
83%
Detected
Mar 13, 2026
signal_type
news
signal_subtype
partners_with

Use this data

Get every partnership signal for PsiQuantum and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at PsiQuantum this week?”

  2. Send it to your own tools

    The Signal API returns partnership signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full news record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/264b3e1b-4dde-4f15-9592-1a883009c54f returns this record as JSON. POST /v1/companies/enrich returns every signal for psiquantum.com.

{
  "signal_id": "264b3e1b-4dde-4f15-9592-1a883009c54f",
  "signal_type": "news",
  "signal_subtype": "partners_with",
  "detected_at": "2026-03-13T10:05:51+00:00",
  "company": {
    "name": "PsiQuantum",
    "domain": "psiquantum.com"
  },
  "data": {
    "url": "https://www.hpcwire.com/off-the-wire/psiquantum-and-national-cancer-center-japan-partner-to-accelerate-drug-discovery-for-healthcare",
    "title": "PsiQuantum and National Cancer Center Japan Partner to Accelerate Drug Discovery for Healthcare",
    "excerpt": "PsiQuantum and National Cancer Center Japan partner to accelerate drug discovery for healthcare.\n\nMarch 12, 2026\n\nPress play to listen to this content\n\nPALO ALTO, Calif., March 12, 2026 - PsiQuantum announced today that the company has signed a collaborative research agreement with the National Cancer Center Japan, a leading cancer treatment and research facility, to advance applications in oncology and healthcare for utility-scale quantum computers. This new agreement underscores the enormous potential for utility-scale quantum computing across the healthcare value chain, specifically in research and development, resource allocation, and patient outcomes in cancer treatment.\n\nUnder the newly formed collaboration, PsiQuantum will work alongside the National Cancer Center Japan to advance fault-tolerant quantum algorithm development and collaborate with the National Cancer Center Japan and other leading pharmaceutical companies in Japan in the development of clinically relevant quantum applications. The partnership will also utilize PsiQuantum's software suite, Construct - a secure, end-to-end platform for designing, analyzing, and optimizing algorithms for fault-tolerant quantum computing.\n\n\"PsiQuantum is proud to work alongside the National Cancer Center Japan as we explore what utility-scale quantum computing will be able to deliver in designing new treatments for the...",
    "summary": "PsiQuantum partners with National Cancer Center.",
    "category": "partners_with",
    "found_at": "2026-03-13T10:05:51Z",
    "planning": false,
    "image_url": "https://www.hpcwire.com/wp-content/uploads/2022/10/PsiQuantum-logo.png",
    "confidence": 0.8303,
    "published_at": "2026-03-12T00:00:00Z",
    "article_sentence": "PsiQuantum and National Cancer Center Japan partner to accelerate drug discovery for healthcare."
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.